---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-004891"
form_type: "8-K"
ticker: "DMAC"
cik: "0001401040"
company_name: "DiaMedica Therapeutics Inc."
filed_at: "2025-02-24T23:59:59+00:00"
generated_at: "2026-05-26T05:41:23.827910+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# DiaMedica Therapeutics appoints Daniel J. O'Connor to Board of Directors

## Summary
- Daniel J. O'Connor appointed to Board effective Feb 20, 2025; joins Audit and Nominating & Corporate Governance Committees.
- O'Connor previously served as CEO of Ambrx Biopharma, guiding it from $40M valuation to $2B acquisition by Johnson & Johnson in 14 months.
- He received option to purchase 64,242 common shares at fair market value, vesting quarterly over three years.
- Initial equity award for non-employee directors increased from 0.12% to 0.15% of outstanding common shares.
- Non-employee director annual equity award also increased from 0.06% to 0.075% of outstanding common shares.

## SEC filing metadata
- accession: 0001437749-25-004891
- form_type: 8-K
- ticker: DMAC
- cik: 0001401040
- company_name: DiaMedica Therapeutics Inc.
- filed_at: 2025-02-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401040/000143774925004891/0001437749-25-004891-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401040/000143774925004891/dmtp20250221_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-004891
- JSON: https://secwatch.observer/filing/0001437749-25-004891.json
- Plain text: https://secwatch.observer/filing/0001437749-25-004891.txt

## Key facts
- Executive change
  Daniel J. O'Connor was appointed as Director at DiaMedica Therapeutics Inc..
  - Action: appointed
  - Role: Director
  source text: On February 20, 2025, the Board of Directors (the “Board”) of DiaMedica Therapeutics Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Daniel J. O’Connor to the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401040/000143774925004891/0001437749-25-004891-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.